Daniela Berg, MD
Chair and Head of the Department of Neurology
- University Clinic of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Building 41, 24103 Kiel, Germany
- +49 431 500 23801
- +49 431 500 24028
- daniela.berg@uksh.de
- https://www.uksh.de/neurologie-kiel
1989 – 1995 Würzburg Medical School, Germany
1996 Medical Thesis (Würzburg Medical School, Germany)
2002 Neurologist (Würzburg Medical School, Germany)
2002 – 2004 Post Doc (Inst. of Human Genetics, University of Tübingen, Germany)
2004 Habilitation (Centre of Neurology, Tübingen, Germany)
2004 – 2006 Senior Resident (Centre of Neurology, Tübingen, Germany)
2006 – 2016 Senior Physician (Centre of Neurology, Tübingen, Germany)
2016 – present Chair and Director of the Department of Neurology, UKSH, Kiel, Germany
2008 – present PI of the TREND study (Tübinger evaluation of Risk factors for Early detection of NeuroDegeneration; https://www.trend-studie.de/)
2010 – present Member of the Scientific Advisory Board of the German Parkinson’s Disease Association (dPV)
2011 – present Board Member of the German Parkinson Society (DPG), Germany
2014 – present Editorial Board Movement Disorders Clinical Practice
2014 – present Associate Editor Journal of Parkinson’s Disease
2015 – 2018 Member of the Scientific Advisory Board of Der Nervenarzt
2015 – present Member of the Parkinson’s UK Research Strategy Board
2016 – present Member of the International Executive Committee of the Movement Disorder Society (MDS)
2018 – present Funding-Co-Editor of DGNeurologie
2018 – present Editorial Board Neurological Research and Practice
1999 Parkinson Prize of the German Neurological Society for the paper “Vulnerability of the nigrostriatal system as detected by transcranial ultrasound”, Neurology 1999
2001 Honourable mention of the Scientific Programme Committee of the International Congress of Parkinson’s disease, Helsinki
2002 Dissertation Prize for Science of the Unterfränkischen Gedenkjahrstiftung
2004 Parkinson Research Grant of the Hilde-Ulrichs-Stiftung (Genetics of Iron Metabolism)
2005 Biomarker Award of the Michael-J-Fox Foundation
2014 Dingebauer Prize of the German Society for Neurology (DGN)
2016 Best review article published in Movement Disorders in 2015: Berg D, Postuma RB, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord 2015;30:1600-11
From 623 original publications; total citations: 20,056; h-index: 73
- Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, Gasser T, Machulla H.-J., Reimold M, Marek K, Berg D. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson’s disease: a prospective blinded study. Lancet Neurol 2008;7:417-24 [IF: 8]
- Maetzler W, Liepelt I, Berg D. Progression of Parkinson’s disease in the clinical phase: potential markers. Lancet Neurol 2009;8:1158-71. [IF: 8]
- Berg D, Seppi K, Behnke S, Liepelt I, Schweitzer K, Stockner H, Wollenweber F, Gaenslen A, Mahlknecht P, Spiegel J, Godau J, Huber H, Srulijes K, Kiechl S, Bentele M, Gasperi A, Schubert T, Hiry T, Probst M, Schneider V, Klenk J, Sawires M, Willeit J, Maetzler W, Fassbender K, Gasser T, Poewe W. Enlarged Substantia Nigra Hyperechogenicity and Risk for Parkinson Disease. A 37-Month 3-Center Study of 1847 Older Persons. Arch Neurol 2011;68:932-7. [IF: 7.0]
- Brockmann K, Hilker R, Pilatus U, Baudrexel S, Srulijes K, Magerkurth J, Hauser AK, Schulte C, Csoti I, Merten CD, Gasser T, Berg D, Hattingen E. GBA-associated PD: Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology 2012;79:213-20. [IF: 3]
- Maetzler W, Pilotto A, Apel A, Deuschle C, Kuebart G, Heinzel S, Liepelt-Scarfone I, Schulte C, Reusch D, Schleicher E, Rothfuss O, Schneider A, Dodel R, Gasser T, Berg D. In vivo markers of Parkinson’s disease and dementia with Lewy bodies: current value of the 5G4 α-synuclein antibody. Acta Neuropathol 2014;128:893-5. [IF: 10.8]
- Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G. MDS research criteria for prodromal Parkinson’s disease. Mov Disord 2015;30:1600-11. [IF: 6.0]
- Postuma RB, Berg D, Adler CH, Bloem BR, Chan P, Deuschl G, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Oertel W, Olanow CW, Poewe W, Stern M. The new definition and diagnostic criteria of Parkinson’s disease. Lancet Neurol 2016;15:546-8. [IF: 26.3]
- Pilotto A, Heinzel S, Suenkel U, Lerche S, Brockmann K, Roeben B, Schaeffer E, Wurster I, Yilmaz R, Liepelt-Scarfone I, von Thaler AK, Metzger FG, Eschweiler GW, Postuma RB, Maetzler W, Berg D. Application of the movement disorder society prodromal Parkinson’s disease research criteria in 2 independent prospective cohorts. Mov Disord 2017;32:1025-1034. [IF: 8.3]
- Berg D, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG, Halliday G, Lang AE, Lewis S, Li Y, Liepelt-Scarfone I, Litvan I, Marek K, Maetzler C, Mi T, Obeso J, Oertel W, Olanow CW, Poewe W, Rios-Romenets S, Schäffer E, Seppi K, Heim B, Slow E, Stern M, Bledsoe IO, Deuschl G, Postuma RB. Movement disorder society criteria for clinically established early Parkinson’s disease. Mov Disord 2018;33:1643-1646. [IF: 8.3]
- Del Din S, Elshehabi M, Galna B, Hobert MA, Warmerdam E, Suenkel U, Brockmann K, Metzger F, Hansen C, Berg D, Rochester L, Maetzler W. Gait analysis with wearables predicts conversion to Parkinson’s disease. Ann Neurol 2019;86:357-367. [IF: 10.2]